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ASSESSING THE VALUE OF LASER IN SITU
KERATOMILEUSIS (LASIK) BY PATIENT
REPORTED OUTCOMES
Kang HY1, Cho WH1, Lee JH2, Lee JM2, Park KH2
1Yonsei University, Seoul, South Korea; 2Chungdam
Balgeunsesang Eye Clinic, Seoul, South Korea
OBJECTIVES: To assess the value of laser in situ ker-
atomileusis (LASIK) by patient-reported outcome of
quality of life (QOL). METHODS: This study included
288 consecutive patients receiving LASIK between July
and December 2001 from 2 eye clinics. Myopia-speciﬁc
Quality of Life Questionnaire (MQLQ) was developed,
including 34 questions in 4 domains: visual function and
symptoms, social role function, and psychological well-
being. Baseline QOL for the condition that refractive
error was corrected by glasses or contact lenses before
LASIK were evaluated by self-administered questionnaire.
The evaluation was repeated at 4 days, 1, 3, and 6 months
after LASIK. All question items were rated on a scale
ranging from 1 (maximal dysfunction) to 5 (no dysfunc-
tion). RESULTS: Average score for the global MQLQ
changed from 3.20 preoperatively to 3.75, 4.00, 4.07,
and 4.12 at 4 days, 1, 3, and 6 months after surgery.
Social role function showed the biggest improvement
(score change: 1.48, p = 0.001), followed by psychologi-
cal well-being (0.98, p = 0.001), visual function (0.67, 
p = 0.001) and symptoms (0.49, p = 0.001). Regression
analysis results showed that the degree of uncorrected
visual acuity, astigmatism, and discomfort with vision
preoperatively were signiﬁcant factors affecting the mag-
nitude of changes in QOL after LASIK. CONCLUSIONS:
This study conﬁrms that the value of LASIK is beyond
the clinical achievement of refractive correction and
extended to the improvement of QOL.
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IMPROVEMENT IN VISION TARGETED QUALITY
OF LIFE (QOL) AFTER CATARACT SURGERY
WITH IMPLANTATION OF ACRYSOF® NATURAL
INTRAOCULAR LENS (IOL)
Venkataraman K, Barnes R
ALCON LABS, Fort Worth,TX, USA
OBJECTIVES: Patients suffering from cataracts have
poor visual acuity that impacts their daily functioning and
well-being. Traditional clinical measures such as visual
acuity do not capture patients’ perceptions of visual func-
tioning and health-related quality of life. This paper
focuses on the interim results of a clinical trial examining
the impact of cataract removal surgery and IOL implan-
tation on vision targeted QoL. METHODS: The 39-item
National Eye Institute- Visual Functioning Questionnaire
(NEI-VFQ) consisting of 12 subscales was used to collect
QoL data during a US-Investigational Device Exemption
(US-IDE) trial comparing the Acrysof® Natural single
piece IOL with Acrysof® single piece IOL. QoL data were
collected via trained telephone interviewers once pre-
operatively (baseline) and twice postoperatively after
cataract surgery and IOL implantation (1–2 month, 
and 4–6 month post-operative visits). RESULTS: Interim
analysis results submitted to the US FDA are described
here. On a scale of 0–100, overall vision targeted QoL
measured as an 11 subscale composite (Overall Vision,
Ocular Pain, Near Activities, Distance Activities, Vision
Social, Role Difﬁculties, Mental Health, Dependency,
Driving, Color Vision, and Peripheral Vision), improved
by over 16 percentage points at the 1–2 month post-
operative visit in both treatment groups, and this
improvement was sustained at the 4–6 month post-
operative visit. Additionally, both treatment groups also
showed similar levels of improvements in all the subscale
scores, including the color vision subscale. CONCLU-
SIONS: The study demonstrates that patients receiving
bilateral cataract surgery and implantation of Acrysof®
Natural single piece lens or Acrysof® single piece lens had
measurable improvement in their vision-targeted QoL
and this improvement is sustained.
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PATIENTS WITH ACUTE CORONARY
SYNDROMES WITHOUT ST-SEGMENT
ELEVATION, ELEVATED TROPONIN T LEVELS
AND DIABETES MELLITUS. OUTCOME AT
THREE MONTHS
Salvador A, Sevilla B, Roldán I, Baello P, Salim M, Peláez A,
Vaquerizo B, Aguar P, Tuzón MT, Mora V, Romero JE
Dr. Peset Hospital,Valencia,Valencia, Spain
OBJECTIVES: Troponin T levels (Tn) are good predic-
tors of outcome in patients with acute coronary sín-
dromes without ST-segment elevation (ACS). Diabetic
patients have demonstrated to carry a worse prognosis
than non-diabetics after having an ACS. METHODS: Tn
were determined in 346 patients (227 men, average age
67.6 years) admitted to hospital after an acute chest pain
episode which was diagnosed as ACS. Plasma sampling
of Tn was made 6 to 24 hours after the clinical episode.
Ninety patients (26%) had diabetes mellitus (D+). Per-
sonal or phone interview of patients or relatives were
obtained three months after the acute episode asking for
endpoints as death, myocardial infarction (MI) or NYHA
III or IV heart failure (HF). RESULTS: Twenty (22.2%)
of all D+ patients had death, MI or HF (RR = 2.7 against
D-; 95% CI = 1.3–5.6; p = 0.008). Tn was equal or higher
than 0.1ng/ml in 133 patients (Tn+ group) and lower
than 0.1ng/ml in the other 213 patients (Tn- group).
Twenty-eight Tn+ patients (21.1%) had death, MI or HF
(RR = 2.8 against T-; 95% CI = 1.6–5.0; p < 0.001).
When age, sex and ST segment changes were also
